Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation

被引:154
作者
Cope, AV
Sabin, C
Burroughs, A
Rolles, K
Griffiths, PD
Emery, VC
机构
[1] ROYAL FREE HOSP, SCH MED, DIV PATHOL & COMMUNICABLE DIS, DEPT VIROL, LONDON NW3 2PF, ENGLAND
[2] ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE, LONDON NW3 2PF, ENGLAND
[3] ROYAL FREE HOSP, SCH MED, DEPT POPULAT SCI, LONDON NW3 2PF, ENGLAND
[4] ROYAL FREE HOSP, SCH MED, LIVER TRANSPLANT UNIT, LONDON NW3 2PF, ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1086/514145
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Longitudinal analysis of 162 liver transplant recipients identified 51 patients who were viremic. Virus load was determined in 47 of these patients using quantitative-competitive polymerase chain reaction, Peak: virus load was significantly higher in 20 symptomatic patients than 27 asymptomatic patients (P < .0001), Elevated virus load, donor seropositivity, and total methylprednisolone dosage were risk factors for human cytomegalovirus (HCMV) disease (odds ratio [OR], 2.22/0.25 log(10) increase in virus load, P = .001; OR, 4.11, P = .05; OR, 130/1-g increment in methylprednisolone, P = .01), Methylprednisolone and virus load were independent risk factors in a multivariate analysis (OR, 2.70/1-g increase, P = .003; OR, 1.61/0.25 log(10) increase, P = .03, respectively). Virus loads of 10(4.75)-10(5.25) genomes/mL of blood were associated with an increased disease probability; the latter was shifted to lower virus loads with increasing quantities of methylprednisolone. These data illustrate the central role of virus load in HCMV pathogenesis.
引用
收藏
页码:1484 / 1490
页数:7
相关论文
共 34 条
[1]   Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients [J].
Badley, AD ;
Patel, R ;
Portela, DF ;
Harmsen, WS ;
Smith, TF ;
Ilstrup, DM ;
Steers, JL ;
Wiesner, RH ;
Paya, CV .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) :446-449
[2]  
Cope AV, 1997, J MED VIROL, V52, P200, DOI 10.1002/(SICI)1096-9071(199706)52:2<200::AID-JMV14>3.0.CO
[3]  
2-O
[4]   USE OF THE POLYMERASE CHAIN-REACTION TO ANALYZE SEQUENCE VARIATION WITHIN A MAJOR NEUTRALIZING EPITOPE OF GLYCOPROTEIN-B (GP58) IN CLINICAL ISOLATES OF HUMAN CYTOMEGALOVIRUS [J].
DARLINGTON, J ;
SUPER, M ;
PATEL, K ;
GRUNDY, JE ;
GRIFFITHS, PD ;
EMERY, VC .
JOURNAL OF GENERAL VIROLOGY, 1991, 72 :1985-1989
[5]   MONITORING LEVELS OF HUMAN CYTOMEGALOVIRUS DNA IN BLOOD AFTER LIVER-TRANSPLANTATION [J].
DROUET, E ;
COLIMON, R ;
MICHELSON, S ;
FOURCADE, N ;
NIVELEAU, A ;
DUCERF, C ;
BOIBIEUX, A ;
CHEVALLIER, M ;
DENOYEL, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (02) :389-394
[6]   QUANTIFICATION OF HUMAN CYTOMEGALOVIRUS DNA USING THE POLYMERASE CHAIN-REACTION [J].
FOX, JC ;
GRIFFITHS, PD ;
EMERY, VC .
JOURNAL OF GENERAL VIROLOGY, 1992, 73 :2405-2408
[7]   LONGITUDINAL ANALYSIS OF CYTOMEGALOVIRUS LOAD IN RENAL-TRANSPLANT RECIPIENTS USING A QUANTITATIVE POLYMERASE CHAIN-REACTION - CORRELATION WITH DISEASE [J].
FOX, JC ;
KIDD, IM ;
GRIFFITHS, PD ;
SWENY, P ;
EMERY, VC .
JOURNAL OF GENERAL VIROLOGY, 1995, 76 :309-319
[8]   PROVISION OF PROGNOSTIC INFORMATION IN IMMUNOCOMPROMISED PATIENTS BY ROUTINE APPLICATION OF THE POLYMERASE CHAIN-REACTION FOR CYTOMEGALOVIRUS [J].
KIDD, IM ;
FOX, JC ;
PILLAY, D ;
CHARMAN, H ;
GRIFFITHS, PD ;
EMERY, VC .
TRANSPLANTATION, 1993, 56 (04) :867-871
[9]   MONITORING OF RENAL-ALLOGRAFT RECIPIENTS BY QUANTITATION OF HUMAN CYTOMEGALOVIRUS GENOMES IN PERIPHERAL-BLOOD LEUKOCYTES [J].
KUHN, JE ;
WENDLAND, T ;
SCHAFER, P ;
MOHRING, K ;
WIELAND, U ;
ELGAS, M ;
EGGERS, HJ .
JOURNAL OF MEDICAL VIROLOGY, 1994, 44 (04) :398-405
[10]  
Lao WC, 1997, J MED VIROL, V51, P152